Pathophysiology: Metabolic Alterations and Risk Factors
Resistant hypertension is a condition often linked to metabolic abnormalities and increased sympathetic nervous activation. One consequence of this might be insulin resistance and impaired glucose metabolism. As resistant hypertension could be further aggravated through unhealthy lifestyle and neglect of drug intake, it is common to see patients with less healthy lifestyle and worse psychosocial conditions also to have difficult-to-treat hypertension, or in many cases even resistant hypertension. Data from a national diabetes register could show that patients with type 2 diabetes fulfilling criteria of resistant hypertension had a worse risk factor profile as compared to other corresponding patients without resistant hypertension. This calls for screening activities to find and target resistant hypertension, as well as measures to improve lifestyle and psychosocial conditions in order to improve compliance with drug medication and improved pharmacological effect of antihypertensive drugs. If this is not enough, other methods such as renal nerve ablation have to be considered.
KeywordsDiabetes Insulin resistance Lifestyle Metabolism Obesity Resistant hypertension
We thank all participating patients, regional coordinators, nurses, and physicians who have contributed to the NDR study. The NDR is supported by the Swedish Society for Diabetology and the Swedish Diabetes Federation. The Swedish Board of Health and Welfare funds the NDR.
There were no conflicts of interest.
- 5.Armario P, Oliveras A, Hernández Del Rey R, Ruilope LM, De La Sierra A (2011) Grupo de Investigadores del Registro de Hipertensión refractaria de la Sociedad Española de Hipertensión/Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). (Prevalence of target organ damage and metabolic abnormalities in resistant hypertension). Med Clin (Barc) 137:435–439Google Scholar
- 8.Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, Riha R, Bassetti C, Narkiewicz K, Mancia G, McNicholas WT (2012) European Respiratory Society; EU COST ACTION B26 members (2012). Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (Cooperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens 30:633–646Google Scholar
- 15.Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G et al (2012) Joint statement of the European Association for the study of obesity and the European Society of hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 30:1047–1055PubMedCrossRefGoogle Scholar
- 17.Pereira CD, Azevedo I, Monteiro R, Martins MJ (2012) 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab doi: 10.1111/j.1463-1326.2012.01582.x (Epub ahead of print)
- 20.Cederholm J, Gudbjörnsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM; on behalf of the NDR (2012). Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II). J Hypertens (Epub ahead of print)Google Scholar